Cerebral Cavernous Malformations and Focal Drug-Resistant Epilepsy: Behind a Quid Pro Quo of Lesion and Epileptogenic

Ionuț-Flavius Bratu1,2, Lucie de Clerck1, Hélène Catenoix3,4

  • 1Department of Epileptology and Cerebral Rhythmology, Timone Hospital, Marseille, France.

PubMed
Abstract

Insights

Stereo-electroencephalography (SEEG) helps map the epileptogenic zone network in cerebral cavernous malformations (CCMs) causing drug-resistant epilepsy. Network-based surgery tailored to the EZN improves seizure freedom in these patients.

Area of Science:

  • Neuroscience
  • Epileptology
  • Neurosurgery

Background:

  • Cerebral cavernous malformations (CCMs) are a cause of focal drug-resistant epilepsy (fDRE).
  • Understanding the relationship between CCMs and epileptogenic zones is crucial for surgical planning.
  • Current surgical outcomes vary due to incomplete knowledge of CCM-epileptogenicity interplay.

Purpose of the Study:

  • To quantify brain structure epileptogenicity in patients with fDRE and supratentorial CCMs using SEEG.
  • To analyze the irritative zone (IZN) and epileptogenic-zone network (EZN) in relation to CCMs.
  • To establish a framework for describing EZN organization within CCM-affected regions.

Main Methods:

  • Retrospective multicentric cohort study of fDRE patients with supratentorial CCMs.
  • Stereo-electroencephalography (SEEG) used for brain region exploration.
  • Classification of SEEG-sampled regions as lesional, perilesional, or non-lesion-associated.
  • Quantification of IZN using spike rates and EZN using Epileptogenicity Index or Permutation Entropy Index.

Main Results:

  • Included 22 patients; 10 underwent epilepsy surgery.
  • IZN biomarkers differed significantly across lesional, perilesional, and non-lesion-associated areas.
  • EZN included lesional areas in 50% of cases, with complex multi-lobar networks in most.
  • 70% of SEEG-explored patients achieved postsurgical seizure freedom.

Conclusions:

  • CCMs exhibit a complex relationship with the epileptogenic zone network (EZN).
  • SEEG is valuable for presurgical work-up in selected CCMs and fDRE patients.
  • A network-based surgical approach, tailored to the EZN, may enhance seizure control.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
293
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
609
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
526
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
648
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
671
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
459